Silexion Therapeutics Files S-1

TL;DR

Silexion Therapeutics (fka Biomotion) filed S-1. Biotech play.

AI Summary

Silexion Therapeutics Corp. filed an S-1 form on February 12, 2025, detailing its business operations. The company, formerly known as Biomotion Sciences until a name change on May 6, 2024, is in the biological products sector. Its business address is located at 12 Abba Hillel Road, Ramat Gan, Israel.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Silexion Therapeutics Corp.'s business, financial status, and future plans as it navigates the biotechnology sector.

Risk Assessment

Risk Level: medium — As a biotechnology company, Silexion Therapeutics likely faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• $0.027 — Exercise Price (Price for fully vested pre-funded options for the Company's ordinary shares.)
• 13,458 — Treasury Shares (Number of treasury shares held by a subsidiary as of December 31, 2023.)

Key Players & Entities

• Silexion Therapeutics Corp. (company) — Filer of the S-1 document
• Biomotion Sciences (company) — Former name of Silexion Therapeutics Corp.
• 20250212 (date) — Filing date of the S-1
• 0002022416 (company) — Central Index Key for Silexion Therapeutics Corp.
• 12 ABBA HILLEL ROAD (address) — Street address of Silexion Therapeutics Corp.
• RAMAT GAN (location) — City of Silexion Therapeutics Corp. business address
• 000000000 (company) — IRS Number for Silexion Therapeutics Corp.

FAQ

Key Financial Figures

• $0.0009 — to 2,377,030 ordinary shares, par value $0.0009 per share (" ordinary shares " or " New
• $1.38 — sales price of our ordinary shares was $1.38 per share and the last reported sales p
• $0.0684 — eported sales price of our warrants was $0.0684 per warrant. We are an "emerging growt
• $15,337,500 — out your approval, including: (a) up to $15,337,500 of ordinary shares issuable under the O
• $3,433,000 — nga Sponsor"), in a principal amount of $3,433,000 (the "A&R Sponsor Promissory Note"), in
• $1,250,000 — nitial public offering, in an amount of $1,250,000 (the "EarlyBird Convertible Note"), eac
• $50,000,000 — lue of Listed Securities (an "MVLS") of $50,000,000. The deficiency was triggered by our MV
• $15,000,000 — of Publicly Held Shares (an "MVPHS") of $15,000,000 for continued listing on the Nasdaq Glo

Filing Documents

• zk2532684.htm (S-1) — 5616KB
• exhibit_5-1.htm (EX-5.1) — 43KB
• exhibit10_3-2.htm (EX-10) — 33KB
• exhibit_23-1.htm (EX-23.1) — 4KB
• exhibit_23-2.htm (EX-23.2) — 6KB
• exhibit_107.htm (EX-FILING FEES) — 30KB
• slxn_img01.jpg (GRAPHIC) — 37KB
• image0.jpg (GRAPHIC) — 385KB
• image1.jpg (GRAPHIC) — 703KB
• image2.jpg (GRAPHIC) — 680KB
• image3.jpg (GRAPHIC) — 308KB
• image4.jpg (GRAPHIC) — 553KB
• image5.jpg (GRAPHIC) — 608KB
• image6.jpg (GRAPHIC) — 1004KB
• image7.jpg (GRAPHIC) — 184KB
• image00008.jpg (GRAPHIC) — 48KB
• image00012.jpg (GRAPHIC) — 5KB
• image00010.jpg (GRAPHIC) — 18KB
• image00009.jpg (GRAPHIC) — 10KB
• 0001178913-25-000443.txt ( ) — 30917KB
• slxn-20240930_pre.xml (EX-101.PRE) — 696KB
• slxn-20240930.xsd (EX-101.SCH) — 146KB
• slxn-20240930_cal.xml (EX-101.CAL) — 41KB
• slxn-20240930_def.xml (EX-101.DEF) — 594KB
• slxn-20240930_lab.xml (EX-101.LAB) — 1259KB
• zk2532684_htm.xml (XML) — 3272KB

Risk Factors

Risk Factors 6 Transactions Related to Offering Under This Prospectus 42 Market and Industry Data 42

Use of Proceeds

Use of Proceeds 43 Determination of Offering Price 44 Market Information for Securities and Dividend Policy 44 Unaudited Pro Forma Condensed Combined Financial Information 44

Management's Discussion and Analysis of Financial Condition and Results of

Management's Discussion and Analysis of Financial Condition and Results of Operations 57

Business

Business 80 Management 109

Executive Compensation

Executive Compensation 115 Certain Relationships and Related Party Transactions 126 Beneficial Ownership of Securities 129 Selling Securityholders 131 Description of Share Capital 135 Material U.S. Federal Income Tax Consequences 142 Plan of Distribution 149 Legal Matters 151 Experts 151 Where You Can Find More Information 152 Index to Financial Statements F-1 You should rely only on the information contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the Securities and Exchange Commission. Neither we nor the Selling Securityholders have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Securityholders is offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: Neither we nor the Selling Securityholders have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States. PROSPECTUS SUMMARY This summary highlights information contained elsewhere in this p

View Full Filing

View this S-1 filing on SEC EDGAR